Lyka Labs
Healthcare
LYKALABS NSE
₹75.57 unchanged 0.00 (0.00%)
- P/E
- Not meaningful: loss-making over the last twelve months
Close 4 Nov 2026 ₹75.57 −18.03 −19.3% 1Y
Start ₹93.60
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- −5.98%
- Debt to Equity
- 0.53
- EPS (TTM)
- −₹2.50
- Book Value
- ₹26.48
- Market Cap
- —
- P/E (TTM)
- Not meaningful: loss-making over the last twelve months
- P/B
- 2.85
- ROE
- −10.20%
- Dividend Yield
- 0.00%
- EBITDA
- ₹0.00
- 52W High
- ₹96.00
- 52W Low
- ₹44.10
- Day Range
- ₹74.06 – ₹75.57
- Volume
- 5,194
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Lyka Labs (this company) | ₹75.57 | — | ₹273 Cr | 2.85 | 0.00% | −10.20% | −5.98% | ₹138 Cr | −₹9 Cr |
| Median 8 companies | ₹1,587.70 | 38.81 | ₹1,25,337 Cr | 4.57 | 0.44% | 16.25% | 16.65% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
38 Weak
Data confidence 91/100
surveillance:ASM2
Category scores
- Quality
- 45
- Weak
- Returns, margins, earnings quality 22% weight
- Valuation
- 28
- Poor
- Cheap vs sector & own history 24% weight
- Growth
- 33
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 24
- Poor
- Solvency, leverage, coverage 9% weight
- Momentum
- 77
- Strong
- Trend strength, vol-adjusted 12% weight
- Ownership
- 50
- Average
- FII/DII/promoter flows 24% weight
Capped: a governance trigger overrides the
fundamentals here (surveillance:ASM2 ≤ 50).
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Company's working capital requirements have reduced from 32.4 days to 22.7 days
Weaknesses
5- Stock is trading at 2.79 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 8.29% over past five years.
- Company has a low return on equity of -2.04% over last 3 years.
- Company might be capitalizing the interest cost
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bearish | 8 | 4 | 7 |
| Oscillators | Bullish | 2 | 4 | 3 |
| Moving Averages | Strong Bearish | 6 | 0 | 4 |
Oscillators
Bullish
Bearish
2
Neutral
4
Bullish
3
Overall
Bearish
Bearish
8
Neutral
4
Bullish
7
Moving Averages
Strong Bearish
Bearish
6
Neutral
0
Bullish
4
Key readings
- RSI (14)
- 41.80
- Neutral
- MACD (12,26,9)
- −0.91
- Bearish
- SMA (50)
- 79.46
- Bearish
- SMA (200)
- 68.12
- Bullish
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | Irregular period |
|---|---|
| 5Y | +8.28% |
| 3Y | +11.24% |
| 1Y | −7.25% |
| TTM | −2.61% |
Net profit
| 10Y | Irregular period |
|---|---|
| 5Y | Loss unchanged |
| 3Y | Loss narrowed by ₹3 Cr |
| 1Y | Turned to loss |
| TTM | Turned to loss |
Operating cash flow
| 10Y | Irregular period |
|---|---|
| 5Y | −11.09% |
| 3Y | −17.79% |
| 1Y | +150.00% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | Irregular period |
|---|---|
| 5Y | −25.60 pp |
| 3Y | −20.62 pp |
| 1Y | −15.38 pp |
| TTM | −14.69 pp |
Revenue by year
| Mar 2017 | ₹110 Cr |
|---|---|
| Mar 2018 | ₹60.00 Cr |
| Mar 2019 | ₹71.00 Cr |
| Mar 2020 | ₹61.00 Cr |
| Mar 2021 | ₹86.00 Cr |
| Mar 2022 | ₹194 Cr |
| Mar 2023 | ₹93.00 Cr |
| Mar 2024 | ₹111 Cr |
| Mar 2025 | ₹138 Cr |
| Mar 2026 | ₹128 Cr |
Net profit by year
| Mar 2017 | −₹7.00 Cr |
|---|---|
| Mar 2018 | −₹19.00 Cr |
| Mar 2019 | −₹6.00 Cr |
| Mar 2020 | −₹63.00 Cr |
| Mar 2021 | −₹10.00 Cr |
| Mar 2022 | ₹38.00 Cr |
| Mar 2023 | −₹13.00 Cr |
| Mar 2024 | −₹3.00 Cr |
| Mar 2025 | ₹8.00 Cr |
| Mar 2026 | −₹10.00 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 22.88 | 27.99 | 32.56 | 27.77 | 30.11 | 41.16 | 33.8 | 33.43 | 33.03 | 36.66 | 30.73 | 28.03 | 42.31 | 44.2 |
| Expenses | 20.24 | 23.82 | 25.69 | 25.75 | 26.4 | 36.21 | 28.61 | 29.35 | 29.35 | 39.2 | 29.08 | 34.48 | 37.76 | 40.68 |
| Operating Profit | 2.64 | 4.17 | 6.87 | 2.02 | 3.71 | 4.95 | 5.19 | 4.08 | 3.68 | −2.54 | 1.65 | −6.45 | 4.55 | 3.52 |
| OPM % | 11.54% | 14.9% | 21.1% | 7.27% | 12.32% | 12.03% | 15.36% | 12.2% | 11.14% | −6.93% | 5.37% | −23.01% | 10.75% | 7.96% |
| Other Income | 0.38 | −0.18 | 0.54 | 0.32 | 0.56 | 0.03 | 0.83 | 0.82 | 0.63 | 1.09 | 1.16 | 0.61 | 0.42 | 0.62 |
| Interest | 1.35 | 1.19 | 1.28 | 1.07 | 0.65 | 0.54 | 0.61 | 0.47 | 0.85 | 0.79 | 0.82 | 0.7 | 1.01 | 1.02 |
| Depreciation | 3.47 | 3.59 | 2.84 | 2.9 | 1.76 | 1.76 | 1.83 | 1.42 | 2.11 | 2.15 | 2.15 | 2.04 | 2.01 | — |
| PBT | −1.8 | −0.79 | 3.29 | −1.63 | 1.86 | 2.67 | 3.57 | 3.01 | 1.35 | −4.38 | −0.16 | −8.58 | 1.95 | 1.07 |
| Tax % | 7.22% | −22.78% | 38.6% | 28.22% | 30.65% | 28.36% | 24.3% | 32.89% | 26.67% | −26.65% | −6.25% | −6.06% | −5.13% | −18.69% |
| Net Profit | −1.93 | −0.49 | 1.78 | −2.09 | 1.29 | 1.91 | 2.7 | 2.03 | 0.99 | −3.21 | −0.15 | −8.07 | 2.05 | 1.27 |
| EPS (₹) | −0.56 | −0.15 | 0.54 | −0.63 | 0.4 | 0.59 | 0.76 | 0.5 | 0.26 | −0.94 | 0 | −2.13 | 0.57 | — |
Sep 2026: from the results filed on 30 Oct 2026, ahead of the full statement, so some rows are blank.
Profit & Loss
₹ Cr| Particulars | Jun 2015 | Mar 2016 9m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 166 | 130 | 110 | 60 | 71 | 61 | 86 | 194 | 93 | 111 | 138 | 128 | 138 |
| Expenses | 139 | 110 | 87 | 63 | 73 | 65 | 67 | 93 | 76 | 95 | 121 | 132 | 141 |
| Operating Profit | 28 | 20 | 23 | −4 | −2 | −4 | 20 | 101 | 17 | 16 | 18 | −3 | −3 |
| OPM % | 17% | 16% | 21% | −6% | −2.7% | −6% | 23% | 52% | 18% | 14% | 13% | −2.7% | −2% |
| Other Income | 4 | 8 | −2 | 4 | 1 | −30 | 0 | −4 | −4 | 1 | 2 | 4 | 3 |
| Interest | 24 | 15 | 19 | 10 | 7 | 20 | 26 | 20 | 12 | 5 | 2 | 3 | 3 |
| Depreciation | 11 | 9 | 10 | 11 | 7 | 8 | 8 | 17 | 14 | 13 | 7 | 8 | 8 |
| PBT | −3 | 4 | −8 | −20 | −15 | −62 | −14 | 59 | −13 | −1 | 11 | −12 | −11 |
| Tax % | 31% | −5% | −19% | −5% | −59% | 1% | −29% | 35% | 0% | 182% | 29% | −11% | — |
| Net Profit | −5 | 4 | −7 | −19 | −6 | −63 | −10 | 38 | −13 | −3 | 8 | −10 | −9 |
| EPS (₹) | −2.29 | 1.67 | −2.51 | −6.14 | −1.97 | −21.1 | −4.03 | 13.59 | −4.3 | −0.75 | 2.24 | −2.81 | −2.5 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 22 | 22 | 22 | 28 | 28 | 29 | 29 | 29 | 31 | 33 | 36 | 36 |
| Reserves | 20 | 22 | 16 | 21 | 15 | −43 | −54 | −15 | 15 | 35 | 69 | 57 |
| Borrowings | 137 | 121 | 126 | 113 | 96 | 141 | 163 | 130 | 75 | 59 | 39 | 49 |
| Other Liabilities | 100 | 77 | 88 | 67 | 76 | 73 | 52 | 42 | 31 | 30 | 32 | 33 |
| Total Liabilities | 279 | 242 | 252 | 229 | 216 | 200 | 190 | 186 | 152 | 157 | 176 | 175 |
| Fixed Assets | 122 | 104 | 133 | 116 | 108 | 105 | 98 | 94 | 68 | 58 | 85 | 87 |
| CWIP | 27 | 30 | 24 | 28 | 31 | 28 | 26 | 18 | 16 | 23 | 1 | 2 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 130 | 107 | 94 | 85 | 77 | 68 | 66 | 74 | 67 | 76 | 90 | 86 |
| Total Assets | 279 | 242 | 252 | 229 | 216 | 200 | 190 | 186 | 152 | 157 | 176 | 175 |
Cash Flow
₹ Cr| Particulars | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 27 | 12 | 31 | 11 | 27 | 5 | 9 | 79 | 9 | 2 | 2 | 5 |
| Investing | 37 | 17 | −13 | −3 | −4 | 0 | 0 | −6 | 7 | −9 | −12 | −9 |
| Financing | −60 | −30 | −19 | −10 | −23 | 3 | −12 | −63 | −22 | 2 | 5 | 4 |
| Net Cash Flow | 4 | −1 | 0 | −3 | −1 | 9 | −3 | 10 | −5 | −6 | −5 | 0 |
| Free Cash Flow | 55 | 28 | 18 | 7 | 23 | 4 | 8 | 72 | 15 | −7 | −10 | −6 |
| CFO/OP | 97 | 60 | 143 | −318 | −1,462 | −131 | 49 | 79 | 52 | 21 | 28 | −159 |
Ratios
| Particulars | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 124 | 121 | 97 | 125 | 75 | 48 | 37 | 35 | 79 | 89 | 114 | 100 |
| Inventory Days | 77 | 56 | 90 | 139 | 65 | 69 | 41 | 56 | 68 | 78 | 82 | 99 |
| Days Payable | 220 | 218 | 266 | 301 | 216 | 192 | 141 | 96 | 91 | 98 | 98 | 122 |
| Cash Conversion Cycle | −18 | −41 | −79 | −37 | −75 | −76 | −63 | −5 | 55 | 68 | 97 | 76 |
| Working Capital Days | −220 | −242 | −357 | −735 | −265 | −242 | −118 | −121 | 0 | 23 | 51 | 23 |
| ROCE % | 10% | 7% | 9% | −8% | −5% | −6% | 10% | 61% | 5% | 4% | 10% | −6% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Lyka Labs insights
65 extracted metrics across FY10–FY27.
Documents
- 10 Aug 2026
- 25 May 2026
- 30 Apr 2026
- 25 Feb 2025
- 19 Dec 2023
- Outcome 30 Oct 2026
Frequently Asked Questions about Lyka Labs
What does Lyka Labs Ltd do?
Incorporated in 1976, Lyka Labs Ltd is in the development, manufacture and marketing of quality finished dosages
Where is Lyka Labs Ltd (LYKALABS) listed?
Lyka Labs Ltd trades as LYKALABS on the NSE and under code 500259 on the BSE.
Which sector does Lyka Labs Ltd belong to?
Lyka Labs Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the 52-week high and low of Lyka Labs Ltd?
Over the last 52 weeks Lyka Labs Ltd has traded between ₹44.1 and ₹96 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Lyka Labs Ltd?
Lyka Labs Ltd reported a return on equity of -10.20%. Its debt-to-equity ratio is 0.53.
Company Information
Incorporated in 1976, Lyka Labs Ltd is in the development, manufacture and marketing of quality finished dosages
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/LYKALABS.md for Lyka Labs Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.